Drug Shortage Report for MAGNESIUM SULFATE INJECTION, USP
Report ID | 136555 |
Drug Identification Number | 02139499 |
Brand name | MAGNESIUM SULFATE INJECTION |
Common or Proper name | Magnesium Sulfate Injection 500 mg/mL SD Vial 10 mL |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | MAGNESIUM SULFATE |
Strength(s) | 500MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS |
Packaging size | 10 mL |
ATC code | B05XA |
ATC description | I.V. SOLUTION ADDITIVES |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2021-04-01 |
Actual start date | 2021-04-01 |
Estimated end date | 2022-04-30 |
Actual end date | 2022-04-30 |
Shortage status | Resolved |
Updated date | 2022-05-01 |
Company comments | On 100% Allocation effective October 13, 2021. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.